TRANSTHERA-B (02617) Administers First Dose in Phase II Trial of Tinengotinib Combined with Fulvestrant for Pretreated HR+/HER2- Breast Cancer

Stock News03-18

TRANSTHERA-B (02617) announced that the first patient has been dosed in a Phase II clinical study of its core product Tinengotinib (TT-00420) in combination with fulvestrant. The trial targets patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative or low-expression (HER2-) recurrent or metastatic breast cancer who have failed prior therapies. This open-label, multicenter, Phase II study, conducted in China, aims to evaluate the safety, efficacy, and pharmacokinetics of Tinengotinib combined with fulvestrant injection in this patient population. The primary target group consists of HR+/HER2- recurrent or metastatic breast cancer patients who have experienced treatment failure after receiving standard therapies, including endocrine treatment and CDK4/6 inhibitors. The study seeks to explore the clinical application value of the Tinengotinib-fulvestrant combination therapy, offering a new treatment option for this resistant breast cancer population. Breast cancer is one of the most common malignant tumors in women globally, with the HR+/HER2- subtype accounting for approximately 70% of all breast cancer cases. Patients in this subgroup often develop resistance and recurrence following standard treatment, creating an urgent clinical need for new effective therapies. Early clinical research results for Tinengotinib have shown encouraging clinical efficacy as a monotherapy in heavily pretreated HR+/HER2- breast cancer patients, supporting further development of its combination with endocrine therapy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131367321?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131367321","market":"hk","top_or_hot":-1,"title":"TRANSTHERA-B (02617) Administers First Dose in Phase II Trial of Tinengotinib Combined with Fulvestrant for Pretreated HR+/HER2- Breast Cancer","media":"Stock News","content":"<p>TRANSTHERA-B (02617) announced that the first patient has been dosed in a Phase II clinical study of its core product Tinengotinib (TT-00420) in combination with fulvestrant. The trial targets patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative or low-expression (HER2-) recurrent or metastatic breast cancer who have failed prior therapies. This open-label, multicenter, Phase II study, conducted in China, aims to evaluate the safety, efficacy, and pharmacokinetics of Tinengotinib combined with fulvestrant injection in this patient population. The primary target group consists of HR+/HER2- recurrent or metastatic breast cancer patients who have experienced treatment failure after receiving standard therapies, including endocrine treatment and CDK4/6 inhibitors. The study seeks to explore the clinical application value of the Tinengotinib-fulvestrant combination therapy, offering a new treatment option for this resistant breast cancer population. Breast cancer is one of the most common malignant tumors in women globally, with the HR+/HER2- subtype accounting for approximately 70% of all breast cancer cases. Patients in this subgroup often develop resistance and recurrence following standard treatment, creating an urgent clinical need for new effective therapies. Early clinical research results for Tinengotinib have shown encouraging clinical efficacy as a monotherapy in heavily pretreated HR+/HER2- breast cancer patients, supporting further development of its combination with endocrine therapy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TRANSTHERA-B (02617) Administers First Dose in Phase II Trial of Tinengotinib Combined with Fulvestrant for Pretreated HR+/HER2- Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTRANSTHERA-B (02617) Administers First Dose in Phase II Trial of Tinengotinib Combined with Fulvestrant for Pretreated HR+/HER2- Breast Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-18 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TRANSTHERA-B (02617) announced that the first patient has been dosed in a Phase II clinical study of its core product Tinengotinib (TT-00420) in combination with fulvestrant. The trial targets patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative or low-expression (HER2-) recurrent or metastatic breast cancer who have failed prior therapies. This open-label, multicenter, Phase II study, conducted in China, aims to evaluate the safety, efficacy, and pharmacokinetics of Tinengotinib combined with fulvestrant injection in this patient population. The primary target group consists of HR+/HER2- recurrent or metastatic breast cancer patients who have experienced treatment failure after receiving standard therapies, including endocrine treatment and CDK4/6 inhibitors. The study seeks to explore the clinical application value of the Tinengotinib-fulvestrant combination therapy, offering a new treatment option for this resistant breast cancer population. Breast cancer is one of the most common malignant tumors in women globally, with the HR+/HER2- subtype accounting for approximately 70% of all breast cancer cases. Patients in this subgroup often develop resistance and recurrence following standard treatment, creating an urgent clinical need for new effective therapies. Early clinical research results for Tinengotinib have shown encouraging clinical efficacy as a monotherapy in heavily pretreated HR+/HER2- breast cancer patients, supporting further development of its combination with endocrine therapy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4225","symbol_name":"医疗保健房地产信托","start_time":0,"source_url":"","article_id":"1131367321","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131367321","pubTimestamp":1773831506,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TRANSTHERA-B (02617) announced that the first patient has been dosed in a Phase II clinical study of its core product Tinengotinib (TT-00420) in combination with fulvestrant. The trial targets...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4225":"医疗保健房地产信托","HR":"医疗保健房地产信托","02617":"药捷安康-B","BK1161":"生物科技","BK4203":"医疗保健房地产投资信托"},"translate_title":"TRANSTHERA-B(02617)在替能替尼联合氟维司群治疗经预处理的HR+/HER2-乳腺癌的II期试验中给予首剂","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1,"HR":1},"content_text":"TRANSTHERA-B (02617) announced that the first patient has been dosed in a Phase II clinical study of its core product Tinengotinib (TT-00420) in combination with fulvestrant. The trial targets patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative or low-expression (HER2-) recurrent or metastatic breast cancer who have failed prior therapies. This open-label, multicenter, Phase II study, conducted in China, aims to evaluate the safety, efficacy, and pharmacokinetics of Tinengotinib combined with fulvestrant injection in this patient population. The primary target group consists of HR+/HER2- recurrent or metastatic breast cancer patients who have experienced treatment failure after receiving standard therapies, including endocrine treatment and CDK4/6 inhibitors. The study seeks to explore the clinical application value of the Tinengotinib-fulvestrant combination therapy, offering a new treatment option for this resistant breast cancer population. Breast cancer is one of the most common malignant tumors in women globally, with the HR+/HER2- subtype accounting for approximately 70% of all breast cancer cases. Patients in this subgroup often develop resistance and recurrence following standard treatment, creating an urgent clinical need for new effective therapies. Early clinical research results for Tinengotinib have shown encouraging clinical efficacy as a monotherapy in heavily pretreated HR+/HER2- breast cancer patients, supporting further development of its combination with endocrine therapy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131367321","isCrawlerRequest":true}